Effect of Moluodan Combined with Rabeprazole in the Treatment of Elderly Chronic Atrophic Gastritis
Objective:To explore the effect of Moluodan combined with Rabeprazole in the treatment of elderly chronic atrophic gastritis.Method:A total of 90 elderly patients with chronic atrophic gastritis who treated in Qichun County People's Hospital from February 2022 to February 2023 were selected as the research objects,they were divided into the study group and the reference group according to the envelope method,with 45 cases in each group.The reference group was treated with Rabeprazole-based conventional therapy,and the study group was treated with Moluodan on the basis of the reference group.The gastrointestinal hormones,serum inflammatory factors,clinical efficacy and adverse reactions were compared between two groups.Result:After treatment,the levels of gastrin (GAS),motilin (MTL) and serum inflammatory factors in two groups were improved compared with those before treatment,the levels of GAS,serum interleukin-6 (IL-6),tumor necrosis factor-α (TNF-α) and high-sensitivity C-reactive protein (hs-CRP) in the study group were lower than those in the reference group,while the level of MTL was higher than that in the reference group,and the differences were statistically significant (P<0.05);the total clinical effective rate of the study group was 95.56％,which was higher than 82.22％ of the reference group,the incidence of adverse reactions in the study group was 8.89％,which was lower than 24.44％ in the reference group,the differences were statistically significant (P<0.05).Conclusion:The combined treatment of Moluodan and Rabeprazole for elderly patients with chronic atrophic gastritis can significantly improve the levels of serum gastrointestinal hormones and inflammatory factors,thereby improving clinical efficacy and controlling adverse reactions.
万方数据
维普
